Discover trends, market shifts, and competitive outlooks for the respiratory disease vaccine industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Respiratory Disease Vaccine Market Growth Evolved From 2024 To 2025, And What’s Ahead?

In recent times, the market size for vaccines treating respiratory diseases has seen a slight increase. The forecast predicts a growth from $69.99 billion in 2024 to $70.9 billion in 2025, implying a compound annual growth rate (CAGR) of 1.3%. Factors such as escalating occurrences of respiratory diseases, heightened cognizance towards public vaccination, public health efforts and a surge in demand for efficient and more bearable vaccines are attributed to the growth observed in the past.

Expectations point towards a stable and gradual increase in the size of the respiratory disease vaccine market over the next few years. By 2029, it is projected to expand up to $79.16 billion with a compound annual growth rate (CAGR) of 2.8%. This upward trend during the forecast period is attributed to factors such as an aging population, escalating healthcare expenditure, investment in vaccines, and preparedness for pandemics. The key trends within this period include vaccine innovation, cooperative research, advancements in vaccine development and drug approvals.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp

What Are the Core Market Drivers Propelling Growth in the Respiratory Disease Vaccine Industry?

The respiratory disease vaccine market is forecasted to accelerate due to the escalating incidence of tuberculosis. This particular respiratory disease, triggered by the bacterium Mycobacterium tuberculosis, primarily affects the lungs and can potentially cause complications in other body systems. The growing incidence of tuberculosis is expected to stimulate the creation and distribution of vaccines against respiratory disease to help curb its spread. To exemplify, the Centers for Disease Control and Prevention, a government agency based in the U.S., reported a rise in tuberculosis cases in November 2023. In 2022, 8,331 tuberculosis cases were recorded, an increase of 5.9% compared to 2021. The incidence rate also jumped to 2.5 cases per 100,000 people, reflecting a 5.5% rise from the prior year. Thus, the escalating incidence of tuberculosis is fuelling the growth of the respiratory disease vaccine market.

Market Driver for Respiratory Disease Vaccine: Escalating Smoking Incidence Fuelling the Market

How Is the Respiratory Disease Vaccine Market Segmented?

The respiratory disease vaccine market covered in this report is segmented –

1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine

2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections

3) By Age: Infant, Adolescent, Adult

4) By End-User: Clinic, Hospital, Other End-Users

Subsegments:

1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine

2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine

3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine, MMRV

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12924&type=smp

Which Regions Are Driving the Next Phase of the Respiratory Disease Vaccine Market Growth?

Asia-Pacific was the largest region in the respiratory disease vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory diseases vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Respiratory Disease Vaccine Industry?

Leading businesses in the respiratory disease vaccine market are focusing on developing innovative offerings with higher effectiveness, aimed at providing better solutions for the prevention and treatment of respiratory disease infections. For example, in May 2023, Pfizer Inc., a pharmaceutical firm based in the United States, gained approval from the Food and Drug Administration (FDA) for ABRYSVO (Respiratory Syncytial Virus Vaccine). This bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine is designated for the prevention of lower respiratory tract disease in individuals aged 60 years and older, specifically those caused by the respiratory syncytial virus. ABRYSVO comprises a duo of tailored preF proteins, which are designed to maximize immunity to both RSV A and B strains. Clinical trials have confirmed its safety and effectiveness.

View the full report here:

https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

How Is the Respiratory Disease Vaccine Market Defined and What Are Its Core Parameters?

Respiratory diseases refer to a wide range of conditions that affect the airways and lungs, leading to respiratory symptoms and impaired breathing. Respiratory disease vaccine refers to a type of vaccine that is an immunization designed to protect individuals from respiratory infections caused by viruses or bacteria that primarily affect the respiratory system, which includes the lungs and airways. These vaccines work by stimulating the immune system to produce antibodies that can recognize and fight the specific pathogen that causes the disease.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12924

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model